NXSL yields 30303.03% · JNJ yields 2.13%● Live data
📍 NXSL pulled ahead of the other in Year 1
Combined, NXSL + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXSL + JNJ for your $10,000?
NexTech FAS Technologies, Inc. engages in the design, manufacture, sale, and servicing of high-precision coating systems and advanced metrology and automation solutions for the semiconductor and flat panel display (FPD) industries. It also involves in the development FAS-Coat, a patented extrusion coating technology for aka spinless coating, slot die coating, and slit coating in the manufacturing process of FPD substrates. The company's products include Altair for testing the repeatability of systems that detect particles on the surface of substrates; Aludra, a reticle inspection system that employs light scattering technology to infer the presence of particles on a semiconductor reticle; Orion, a reticle inspection system, which provides inspection for semiconductor reticles and photomasks; FPDStar, an optical inspection system for identifying and mapping pattern, particle, and processing defects on FPD/TFT substrates; and NexTStar, an automated optical inspection system that represents breakthrough performance in FPD pattern, particle, and processing defect detection. Its products also comprise Pegasu, a wafer sorter series that provides standards-compliant user and automation interfaces; Proteus Reticle Load Port Upgrade kit, a hardware and software solution; and PST upgrades for wafer sorters. In addition, the company's FAS-Coat coating systems process substrates for the flat panel display, multi-chip module, solar cell, biomedical, and semiconductor industries. It was formerly known as NexTech Solutions, Inc. and changed its name to NexTech FAS Technologies, Inc. in July 2007. The company is headquartered in Austin, Texas.
Full NXSL Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.